Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,584 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Complement lectin pathway activation is associated with COVID-19 disease severity, independent of MBL2 genotype subgroups.
Hurler L, Szilágyi Á, Mescia F, Bergamaschi L, Mező B, Sinkovits G, Réti M, Müller V, Iványi Z, Gál J, Gopcsa L, Reményi P, Szathmáry B, Lakatos B, Szlávik J, Bobek I, Prohászka ZZ, Förhécz Z, Csuka D, Kajdácsi E, Cervenak L, Kiszel P, Masszi T, Vályi-Nagy I, Würzner R; Cambridge Institute of Therapeutic Immunology and Infectious Disease-National Institute of Health Research (CITIID-NIHR) COVID BioResource Collaboration; Lyons PA, Toonen EJM, Prohászka Z. Hurler L, et al. Among authors: muller v. Front Immunol. 2023 Mar 27;14:1162171. doi: 10.3389/fimmu.2023.1162171. eCollection 2023. Front Immunol. 2023. PMID: 37051252 Free PMC article.
Complement Overactivation and Consumption Predicts In-Hospital Mortality in SARS-CoV-2 Infection.
Sinkovits G, Mező B, Réti M, Müller V, Iványi Z, Gál J, Gopcsa L, Reményi P, Szathmáry B, Lakatos B, Szlávik J, Bobek I, Prohászka ZZ, Förhécz Z, Csuka D, Hurler L, Kajdácsi E, Cervenak L, Kiszel P, Masszi T, Vályi-Nagy I, Prohászka Z. Sinkovits G, et al. Among authors: muller v. Front Immunol. 2021 Mar 25;12:663187. doi: 10.3389/fimmu.2021.663187. eCollection 2021. Front Immunol. 2021. PMID: 33841446 Free PMC article. Clinical Trial.
Associations between the von Willebrand Factor-ADAMTS13 Axis, Complement Activation, and COVID-19 Severity and Mortality.
Sinkovits G, Réti M, Müller V, Iványi Z, Gál J, Gopcsa L, Reményi P, Szathmáry B, Lakatos B, Szlávik J, Bobek I, Prohászka ZZ, Förhécz Z, Mező B, Csuka D, Hurler L, Kajdácsi E, Cervenak L, Kiszel P, Masszi T, Vályi-Nagy I, Prohászka Z. Sinkovits G, et al. Among authors: muller v. Thromb Haemost. 2022 Feb;122(2):240-256. doi: 10.1055/s-0041-1740182. Epub 2022 Jan 21. Thromb Haemost. 2022. PMID: 35062036 Free PMC article.
Complement Levels at Admission Reflecting Progression to Severe Acute Kidney Injury (AKI) in Coronavirus Disease 2019 (COVID-19): A Multicenter Prospective Cohort Study.
Henry BM, Sinkovits G, Szergyuk I, de Oliveira MHS, Lippi G, Benoit JL, Favaloro EJ, Pode-Shakked N, Benoit SW, Cooper DS, Müller V, Iványi Z, Gál J, Réti M, Gopcsa L, Reményi P, Szathmáry B, Lakatos B, Szlávik J, Bobek I, Prohászka ZZ, Förhécz Z, Csuka D, Hurler L, Kajdácsi E, Cervenak L, Mező B, Kiszel P, Masszi T, Vályi-Nagy I, Prohászka Z. Henry BM, et al. Among authors: muller v. Front Med (Lausanne). 2022 Apr 29;9:796109. doi: 10.3389/fmed.2022.796109. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35572977 Free PMC article.
Nationwide Effectiveness of First and Second SARS-CoV2 Booster Vaccines During the Delta and Omicron Pandemic Waves in Hungary (HUN-VE 2 Study).
Kiss Z, Wittmann I, Polivka L, Surján G, Surján O, Barcza Z, Molnár GA, Nagy D, Müller V, Bogos K, Nagy P, Kenessey I, Wéber A, Pálosi M, Szlávik J, Schaff Z, Szekanecz Z, Müller C, Kásler M, Vokó Z. Kiss Z, et al. Among authors: muller v, muller c. Front Immunol. 2022 Jun 23;13:905585. doi: 10.3389/fimmu.2022.905585. eCollection 2022. Front Immunol. 2022. PMID: 35812442 Free PMC article.
Booster Vaccination Decreases 28-Day All-Cause Mortality of the Elderly Hospitalized Due to SARS-CoV-2 Delta Variant.
Müller V, Polivka L, Valyi-Nagy I, Nagy A, Szekanecz Z, Bogos K, Vago H, Kamondi A, Fekete F, Szlavik J, Elek J, Surján G, Surján O, Nagy P, Schaff Z, Müller C, Kiss Z, Kásler M. Müller V, et al. Among authors: muller c. Vaccines (Basel). 2022 Jun 21;10(7):986. doi: 10.3390/vaccines10070986. Vaccines (Basel). 2022. PMID: 35891151 Free PMC article.
Effectiveness and Waning of Protection With Different SARS-CoV-2 Primary and Booster Vaccines During the Delta Pandemic Wave in 2021 in Hungary (HUN-VE 3 Study).
Vokó Z, Kiss Z, Surján G, Surján O, Barcza Z, Wittmann I, Molnár GA, Nagy D, Müller V, Bogos K, Nagy P, Kenessey I, Wéber A, Polivka L, Pálosi M, Szlávik J, Rokszin G, Müller C, Szekanecz Z, Kásler M. Vokó Z, et al. Among authors: muller v, muller c. Front Immunol. 2022 Jul 22;13:919408. doi: 10.3389/fimmu.2022.919408. eCollection 2022. Front Immunol. 2022. PMID: 35935993 Free PMC article.
Waning of SARS-CoV-2 Vaccine Effectiveness in COPD Patients: Lessons from the Delta Variant.
Polivka L, Valyi-Nagy I, Szekanecz Z, Bogos K, Vago H, Kamondi A, Fekete F, Szlavik J, Surjan G, Surjan O, Nagy P, Schaff Z, Kiss Z, Müller C, Kasler M, Müller V. Polivka L, et al. Among authors: muller v, muller c. Vaccines (Basel). 2023 Nov 29;11(12):1786. doi: 10.3390/vaccines11121786. Vaccines (Basel). 2023. PMID: 38140190 Free PMC article.
[Antiviral and anti-inflammatory therapies in COVID-19].
Szekanecz Z, Bogos K, Constantin T, Fülesdi B, Müller V, Rákóczi É, Várkonyi I, Vályi-Nagy I. Szekanecz Z, et al. Among authors: muller v. Orv Hetil. 2021 Apr 10;162(17):643-651. doi: 10.1556/650.2021.32230. Orv Hetil. 2021. PMID: 33838023 Hungarian.
What is really 'Long COVID'?
Szabo S, Zayachkivska O, Hussain A, Muller V. Szabo S, et al. Among authors: muller v. Inflammopharmacology. 2023 Apr;31(2):551-557. doi: 10.1007/s10787-023-01194-0. Epub 2023 Mar 25. Inflammopharmacology. 2023. PMID: 36964860 Free PMC article. Review.
1,584 results